Evaluation of predictors of response to first-line therapy for treatment of grade II-IV acute GVHD
| Predictor . | No. of patients . | CR/PR, no. of patients (%) . | Univariate . | Multivariate . | ||||
|---|---|---|---|---|---|---|---|---|
| OR . | 95% CI . | P . | OR . | 95% CI . | P . | |||
| Patient age | ||||||||
| Older than 45 y | 149 | 73 (49) | 1.5 | 0.9-2.5 | .1 | — | — | — |
| 45 y or younger | 110 | 43 (39) | 1.0 | Reference | — | — | — | — |
| Patient sex | ||||||||
| Female | 97 | 39 (40) | 0.7 | 0.4-1.2 | .25 | — | — | — |
| Male | 162 | 77 (47) | 1.0 | Reference | — | — | — | — |
| Donor/patient sex* | ||||||||
| Female/male | 73 | 81 (44) | 1.04 | 0.6-1.8 | .9 | — | — | — |
| Other | 184 | 33 (45) | 1.0 | Reference | — | — | — | — |
| Acute GVHD | ||||||||
| Hyperacute GVHD | 73 | 25 (34) | 0.5 | 0.3-0.9 | .03 | — | — | — |
| Other acute GVHD | 186 | 91 (49) | 1.0 | Reference | — | — | — | — |
| Donor type | ||||||||
| Mrel | 134 | 68 (51) | 1.0 | Reference | — | — | — | — |
| MUD | 95 | 41 (43) | 0.7 | 0.4-1.2 | .2 | — | — | — |
| MMrel | 30 | 7 (23) | 0.3 | 0.1-0.7 | .009 | — | — | — |
| MMrel vs other | NA | NA | 0.3 | 0.1-0.8 | .02 | — | — | — |
| Donor type/hyperacute GVHD | ||||||||
| Mrel and no hyperacute | 106 | 53 (50) | 1.0 | Reference | — | — | — | — |
| Mrel and hyperacute | 28 | 15 (54) | 1.1 | 0.5-2.7 | .7 | — | — | — |
| MUD/MMrel and no hyperacute | 80 | 38 (47) | 0.9 | 0.5-1.6 | .7 | — | — | — |
| MUD/MMrel and hyperacute | 45 | 10 (22) | 0.3 | 0.1-0.6 | .002 | 0.3 | 0.1-0.6 | .002 |
| Cell source in Mrel | ||||||||
| PB | 116 | 58 (50) | 0.8 | 0.3-2.2 | .7 | — | — | — |
| BM | 18 | 10 (56) | 1.0 | Reference | — | — | — | — |
| Conditioning regimen | ||||||||
| Reduced intensity | 83 | 37 (45) | 1.0 | Reference | — | — | — | — |
| High-dose chemotherapy | 139 | 65 (47) | 1.1 | 0.6-1.9 | .7 | — | — | — |
| TBI | 37 | 14 (38) | 0.8 | 0.3-1.7 | .5 | — | — | — |
| Diagnosis | ||||||||
| Myeloid | 140 | 59 (42) | 0.7 | 0.4-1.3 | .3 | — | — | — |
| Lymphoid | 93 | 46 (49) | 1.0 | Reference | — | — | — | — |
| Multiple myeloma | 10 | 3 (30) | 0.4 | 0.1-1.8 | .2 | — | — | — |
| Solid tumor/other | 16 | 8 (50) | 1.02 | 0.3-2.9 | .96 | — | — | — |
| Disease status at transplantation | ||||||||
| Not in remission | 176 | 86 (49) | 1.7 | 0.98-2.9 | .06 | 1.6 | 0.9-2.7 | .1 |
| Remission | 83 | 30 (36) | 1.0 | Reference | — | 1.0 | Reference | — |
| Predictor . | No. of patients . | CR/PR, no. of patients (%) . | Univariate . | Multivariate . | ||||
|---|---|---|---|---|---|---|---|---|
| OR . | 95% CI . | P . | OR . | 95% CI . | P . | |||
| Patient age | ||||||||
| Older than 45 y | 149 | 73 (49) | 1.5 | 0.9-2.5 | .1 | — | — | — |
| 45 y or younger | 110 | 43 (39) | 1.0 | Reference | — | — | — | — |
| Patient sex | ||||||||
| Female | 97 | 39 (40) | 0.7 | 0.4-1.2 | .25 | — | — | — |
| Male | 162 | 77 (47) | 1.0 | Reference | — | — | — | — |
| Donor/patient sex* | ||||||||
| Female/male | 73 | 81 (44) | 1.04 | 0.6-1.8 | .9 | — | — | — |
| Other | 184 | 33 (45) | 1.0 | Reference | — | — | — | — |
| Acute GVHD | ||||||||
| Hyperacute GVHD | 73 | 25 (34) | 0.5 | 0.3-0.9 | .03 | — | — | — |
| Other acute GVHD | 186 | 91 (49) | 1.0 | Reference | — | — | — | — |
| Donor type | ||||||||
| Mrel | 134 | 68 (51) | 1.0 | Reference | — | — | — | — |
| MUD | 95 | 41 (43) | 0.7 | 0.4-1.2 | .2 | — | — | — |
| MMrel | 30 | 7 (23) | 0.3 | 0.1-0.7 | .009 | — | — | — |
| MMrel vs other | NA | NA | 0.3 | 0.1-0.8 | .02 | — | — | — |
| Donor type/hyperacute GVHD | ||||||||
| Mrel and no hyperacute | 106 | 53 (50) | 1.0 | Reference | — | — | — | — |
| Mrel and hyperacute | 28 | 15 (54) | 1.1 | 0.5-2.7 | .7 | — | — | — |
| MUD/MMrel and no hyperacute | 80 | 38 (47) | 0.9 | 0.5-1.6 | .7 | — | — | — |
| MUD/MMrel and hyperacute | 45 | 10 (22) | 0.3 | 0.1-0.6 | .002 | 0.3 | 0.1-0.6 | .002 |
| Cell source in Mrel | ||||||||
| PB | 116 | 58 (50) | 0.8 | 0.3-2.2 | .7 | — | — | — |
| BM | 18 | 10 (56) | 1.0 | Reference | — | — | — | — |
| Conditioning regimen | ||||||||
| Reduced intensity | 83 | 37 (45) | 1.0 | Reference | — | — | — | — |
| High-dose chemotherapy | 139 | 65 (47) | 1.1 | 0.6-1.9 | .7 | — | — | — |
| TBI | 37 | 14 (38) | 0.8 | 0.3-1.7 | .5 | — | — | — |
| Diagnosis | ||||||||
| Myeloid | 140 | 59 (42) | 0.7 | 0.4-1.3 | .3 | — | — | — |
| Lymphoid | 93 | 46 (49) | 1.0 | Reference | — | — | — | — |
| Multiple myeloma | 10 | 3 (30) | 0.4 | 0.1-1.8 | .2 | — | — | — |
| Solid tumor/other | 16 | 8 (50) | 1.02 | 0.3-2.9 | .96 | — | — | — |
| Disease status at transplantation | ||||||||
| Not in remission | 176 | 86 (49) | 1.7 | 0.98-2.9 | .06 | 1.6 | 0.9-2.7 | .1 |
| Remission | 83 | 30 (36) | 1.0 | Reference | — | 1.0 | Reference | — |
Total number of patients is 259; total number experiencing either CR or PR is 116. Analysis excludes 6 patients with unknown response.
—indicates not applicable.
Donor sex is unknown for 2 patients.